Healthcare & Life Sciences
Syntax Bio
United States
activeseries-a
series-a
Stage
2
Investors
About
Syntax Bio develops faster methods for cell therapy by using transient plasmids to deliver CRISPR-based instructions that accelerate stem cell differentiation, making cell therapies more affordable and accessible.
Explore Syntax Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.